浏览全部资源
扫码关注微信
磷酸化FGFR1Y654在食管鳞状细胞癌中的表达及临床意义
Expression and clinical significance of phosphorylated FGFR1Y654 in esophageal squamous cell carcinoma
- 陆军军医大学学报 2024年46卷第3期 页码：257-264
- 作者机构：
1.610031 成都，西南交通大学医学院临床医学系
2.610083 成都，中国人民解放军西部战区总医院肿瘤科
- 作者简介：
[ 程朋，E-mail：chp912@sina.com CHENG Peng, E-mail: chp912@sina.com
- 基金信息：国家自然科学基金青年科学基金项目(82102920)
DOI：10.16016/j.2097-0927.202306015
中图分类号： R345.57;R730.23;R735.1收稿：2023-06-05，
修回：2023-09-05，
纸质出版：2024-02-15
- 稿件说明：
移动端阅览
杜丹, 李静, 罗洪, 等. 磷酸化FGFR1Y654在食管鳞状细胞癌中的表达及临床意义[J]. 陆军军医大学学报, 2024,46(3):257-264.
Dan DU, Jing LI, Hong LUO, et al. Expression and clinical significance of phosphorylated FGFR1Y654 in esophageal squamous cell carcinoma[J]. Journal of Army Medical University, 2024, 46(3): 257-264.
杜丹, 李静, 罗洪, 等. 磷酸化FGFR1Y654在食管鳞状细胞癌中的表达及临床意义[J]. 陆军军医大学学报, 2024,46(3):257-264. DOI： 10.16016/j.2097-0927.202306015.
Dan DU, Jing LI, Hong LUO, et al. Expression and clinical significance of phosphorylated FGFR1Y654 in esophageal squamous cell carcinoma[J]. Journal of Army Medical University, 2024, 46(3): 257-264. DOI： 10.16016/j.2097-0927.202306015.
摘要
目的
2
探讨磷酸化FGFR1
Y654
(p-FGFR1
Y654
)的表达与食管鳞状细胞癌患者临床病理特征之间的关系及其预后价值。
方法
2
收集西部战区总医院2017年1月至2020年7月间进行食管鳞状细胞癌手术切除的肿瘤组织标本103例及正常组织58例，采用免疫组化法检测组织中p-FGFR1
Y654
的表达情况，并分析其与临床病理参数和预后的相关性。
结果
2
p-FGFR1
Y654
在食管鳞状细胞癌组织中的表达显著高于正常组织(
P
＜0.01)。p-FGFR1
Y654
的表达水平与总生存期(overall survival
OS)密切相关(
P
＜0.05)，与患者年龄、性别、肿瘤分期、肿瘤长径等无关。多因素COX回归分析表明N分期是影响患者无复发生存时间(recurrence free survival，RFS)的独立预后因素。生存分析显示，p-FGFR1
Y654
低表达组患者的RFS明显优于高表达组(
P
=0.032，95%
CI
: 1.08~4.65)，且p-FGFR1
Y654
低表达组患者OS也明显优于高表达组(
P
=0.004，95%
CI
: 2.14~11.51)。
结论
2
p-FGFR1
Y654
在食管鳞状细胞癌组织中高表达，且与患者不良预后相关，p-FGFR1
Y654
可能成为食管鳞状细胞癌的潜在治疗靶点。
Abstract
Objective
2
To explore the relationship between p-FGFR1
Y654
expression and clinical pathological characteristics of esophageal squamous cell carcinoma
patients and its prognostic value.
Methods
2
Tumor tissue samples from 103 cases of esophageal squamous cell carcinoma and 58 normal esophageal tissues were surgically collected in the General Hospital of Western Theater between January 2017 and July 2020. The expression of p-FGFR1
Y654
in the tissues was detected using immunohistochemical assay
and its correlation with relevant clinicopathological parameters and prognosis was analyzed.
Results
2
The expression of p-FGFR1
Y654
in esophageal squamous cell carcinoma tissues was significantly higher than that in normal tissue (
P
<
0.01). Its expression level was closely related to overall survival (OS
P
<
0.05)
but not related to age
gender
tumor stage or tumor size. Multivariate COX regression analysis showed that N-stage was identified as an independent prognostic factor for recurrence free survival (RFS) in esophageal squamous cell carcinoma patients. Survival analysis indicated that patients with low expression of p-FGFR1
Y654
had significantly higher RFS and OS than those with high expression (
P
=0.032
95%
CI
: 1.08~4.65;
P
=0.004
95%
CI
: 2.14~11.51).
Conclusion
2
p-FGFR1
Y654
is highly expressed in esophageal squamous cell carcinoma tissue
and is associated with poor prognosis in these patients. p-FGFR1
Y654
may be a potential therapeutic target for esophageal squamous cell carcinoma.
关键词
Keywords
references
SUNG H, FERLAY J, SIEGEL R L, et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
PAKZAD R, MOHAMMADIAN-HAFSHEJANI A, KHOSRAVI B, et al . The incidence and mortality of esophageal cancer and their relationship to development in Asia[J ] . Ann Transl Med, 2016, 4(2): 29. DOI: 10.3978/j. issn.2305-5839.2016.01.11.
ZENG H M, CHEN W Q, ZHENG R S, et al . Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J ] . Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
DIGKLIA A, VOUTSADAKIS I A. Targeted treatments for metastatic esophageal squamous cell cancer[J]. World J Gastrointest Oncol, 2013, 5(5): 88-96. DOI: 10.4251/wjgo.v5.i5.88.
ROSKOSKI R Jr. The role of fibroblast growth factor receptor(FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder[J]. Pharmacol Res, 2020, 151: 104567. DOI: 10.1016/j.phrs.2019.104567.
WANG Y, WU Y M, LI J L, et al . Prognostic and clinicopathological significance of FGFR1 gene amplification in resected esophageal squamous cell carcinoma: a meta-analysis[J ] . Ann Transl Med, 2019, 7(22): 669. DOI: 10.21037/atm.2019.10.69.
TURNER N, GROSE R. Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer, 2010, 10(2): 116-129. DOI: 10.1038/nrc2780.
XIE Y L, SU N, YANG J, et al . FGF/FGFR signaling in health and disease[J ] . Signal Transduct Target Ther, 2020, 5(1): 181. DOI: 10.1038/s41392-020-00222-7.
SHIMIZU D, SAITO T, ITO S, et al . Overexpression of FGFR1 promotes peritoneal dissemination via epithelial-to-mesenchymal transition in gastric cancer[J ] . Cancer Genom Proteom, 2018, 15(4): 313-320. DOI: 10.21873/cgp.20089..
LUO H, QUAN J, XIAO H, et al . FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial-mesenchymal transition to gefitinib[J ] . Oncol Rep, 2018: 39(5): 2270-2278. DOI: 10.3892/or.2018.6304.
FURDUI C M, LEW E D, SCHLESSINGER J, et al . Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction[J ] . Mol Cell, 2006, 21(5): 711-717. DOI: 10.1016/j.molcel.2006.01.022.
XIE F J, LU H Y, ZHENG Q Q, et al . The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis[J ] . Onco Targets Ther, 2016, 9: 171-181. DOI: 10.2147/OTT.S91848.
KIM E K, CHO Y A, KOH Y W, et al . Prognostic implications of fibroblast growth factor receptor 1(FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma[J ] . BMC Cancer, 2020, 20(1): 348. DOI: 10.1186/s12885-020-06792-7.
VON LOGA K, KOHLHAUSSEN J, BURKHARDT L, et al . FGFR1 amplification is often homogeneous and strongly linked to the squamous cell carcinoma subtype in esophageal carcinoma[J ] . PLoS One, 2015, 10(11): e0141867. DOI: 10.1371/journal.pone.0141867.
CHEN B Q, LIU S R, GAN L, et al . FGFR1 signaling potentiates tumor growth and predicts poor prognosis in esophageal squamous cell carcinoma patients[J ] . Cancer Biol Ther, 2018, 19(1): 76-86. DOI: 10.1080/15384047.2017.1394541.
WU J Q, WANG Y H, LIU J, et al . Effects of FGFR1 gene polymorphisms on the risk of breast cancer and FGFR1 protein expression[J ] . Cell Physiol Biochem, 2018, 47(6): 2569-2578. DOI: 10.1159/000491653.
HU Y, AI L S, ZHOU L Q. Prognostic value of FGFR1 expression and amplification in patients with HNSCC: a systematic review and meta-analysis[J]. PLoS One, 2021, 16(5): e0251202. DOI: 10.1371/journal.pone.0251202.
PALAKURTHI S, KURAGUCHI M, ZACHAREK S J, et al . The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity[J ] . Cancer Immunol Res, 2019, 7(9): 1457-1471. DOI: 10.1158/2326-6066.CIR-18-0595.
TURNER N, GROSE R. Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer, 2010, 10(2): 116-129. DOI: 10.1038/nrc2780.
JI W X, YU Y F, LI Z M, et al . FGFR1 promotes the stem cell-like phenotype of FGFR1-amplified non-small cell lung cancer cells through the Hedgehog pathway[J ] . Oncotarget, 2016, 7(12): 15118-15134. DOI:10.18632/oncotarget.7701.
0
浏览量
0
下载量
0
CSCD
- 网络PDF下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
